Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer

被引:46
作者
Chien, Jeremy R.
Aletti, Giovanni
Bell, Debra A.
Keeney, Gary L.
Shridhar, Viji
Hartmann, Lynn C.
机构
[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Gynecol Surg, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Anat Pathol, Rochester, MN 55905 USA
关键词
molecular pathogenesis; therapeutic targets; ovarian cancer;
D O I
10.1002/jcb.21552
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate
引用
收藏
页码:1117 / 1129
页数:13
相关论文
共 79 条
[1]
Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide [J].
Abramson, N ;
Stokes, PK ;
Luke, M ;
Marks, AR ;
Harris, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :1147-1149
[2]
ADAMS AT, 1981, CANCER RES, V41, P2063
[3]
Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[4]
Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[5]
Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
[6]
Aletti GD, 2007, MAYO CLIN PROC, V82, P751
[7]
Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer [J].
Bapat, SA ;
Mali, AM ;
Koppikar, CB ;
Kurrey, NK .
CANCER RESEARCH, 2005, 65 (08) :3025-3029
[8]
Bayani J, 2002, CANCER RES, V62, P3466
[9]
Origins and molecular pathology of ovarian cancer [J].
Bell, DA .
MODERN PATHOLOGY, 2005, 18 :S19-S32
[10]
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days [J].
Benson, C. ;
White, J. ;
De Bono, J. ;
O'Donnell, A. ;
Raynaud, F. ;
Cruickshank, C. ;
McGrath, H. ;
Walton, M. ;
Workman, P. ;
Kaye, S. ;
Cassidy, J. ;
Gianella-Borradori, A. ;
Judson, I. ;
Twelves, C. .
BRITISH JOURNAL OF CANCER, 2007, 96 (01) :29-37